迈向镰状细胞病的造血干细胞移植与实体器官移植双重移植
本综述总结镰状细胞病(SCD)中造血干细胞移植(HSCT)与实体器官移植的现状,探讨双重HSCT/实体器官移植的未来方向与临床可行性。SCD导致反复血管闭塞危象和慢性终末器官损伤;HSCT可能治愈但存在已知并发症风险,而器官衰竭患者可考虑实体器官移植,但移植器官有被原发病损伤的风险。
要点
- HSCT对SCD可能治愈,但与已知并发症风险和死亡相关,理想情况下仅提供给高风险显著并发症的患者。
- 在显著并发症发生前识别高风险患者困难,而一旦发生显著器官损伤,患者被认为不适合HSCT。
- 双重HSCT与器官移植可同时替换衰竭器官并消除 underlying 疾病过程。
核心结论
- 双重HSCT和器官移植可同时替换衰竭器官并消除 underlying 疾病过程。
- HSCT预处理方案的进展如减低强度方案和替代供者选择可能扩大移植的可行性和潜在供者池。
研究设计与样本
- 综述,总结SCD中HSCT和器官移植的现状并讨论双重HSCT/实体器官移植的未来方向与临床可行性。
主要发现
- SCD导致反复血管闭塞危象、慢性终末器官损伤及相关的躯体、心理和社会功能障碍。
- HSCT对SCD可能治愈,但与已知并发症风险和死亡相关,理想情况下仅提供给高风险显著并发症的患者。
- 在显著并发症发生前识别高风险患者困难,而一旦发生显著器官损伤,患者被认为不适合HSCT。
- 因SCD长期器官毒性如肾或肝衰竭的患者可能成为实体器官移植的候选者,但移植器官有被原发病损伤的风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle-cell disease (SCD) leads to recurrent vaso-occlusive crises, chronic end-organ damage, and resultant physical, psychological, and social disabilities. Although hematopoietic stem-cell transplantation (HSCT) is potentially curative for SCD, this procedure is associated with well-recognized morbidity and mortality and thus is ideally offered only to patients at high risk of significant complications. However, it is difficult to identify patients at high risk before significant complications have occurred, and once patients experience significant organ damage, they are considered poor candidates for HSCT. In turn, patients who have experienced long-term organ toxicity from SCD such as renal or liver failure may be candidates for solid-organ transplantation (SOT); however, the transplanted organs are at risk of damage by the original disease. Thus, dual HSCT and organ transplantation could simultaneously replace the failing organ and eliminate the underlying disease process. Advances in HSCT conditioning such as reduced-intensity regimens and alternative donor selection may expand both the feasibility of and potential donor pool for transplantation. This review summarizes the current state of HSCT and organ transplantation in SCD and discusses future directions and the clinical feasibility of dual HSCT/SOT.
引用
- Hosoya H, Levine J, Abt P, et al. Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. Blood Adv. 2018. PMID: 29535106. doi:10.1182/bloodadvances.2017012500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。